Cancer Stem Cell News Volume 5.22 | Jun 8 2016

TOP STORY

MiR-26a Inhibits Stem Cell-Like Phenotype and Tumor Growth of Osteosarcoma by Targeting Jagged1

Investigators demonstrated that miR-26a is downregulated in osteosarcoma cancer stem cells when derived by either sarcosphere generation, chemodrug or aldehyde dehydrogenase activity selection. [Oncogene] Abstract

(Ranked by impact factor of the journal)

The Long Non-Coding RNA HIF1A-AS2 Facilitates the Maintenance of Mesenchymal Glioblastoma Stem-Like Cells in Hypoxic Niches

The authors identified hypoxia-inducible factor 1 alpha-antisense RNA 2 (HIF1A-AS2) as a subtype-specific hypoxia-inducible long non-coding RNAs, upregulated in mesenchymal glioblastoma multiforme stem-like cells. [Cell Rep] Full Article | Graphical Abstract

Tumor Acidosis Enhances Cytotoxic Effects and Autophagy Inhibition by Salinomycin on Cancer Cell Lines and Cancer Stem Cells

Investigators identified salinomycin as a potent inhibitor of autophagy and cytotoxic agent effective on several cancer cell lines under conditions of transient and chronic acidosis. [Oncotarget] Full Article

MtDNA Depleted PC3 Cells Exhibit Warburg Effect and Cancer Stem Cell Features

Scientists demonstrated that human castration resistant prostate cancer cell line PC3 tolerated high concentration of the mtDNA replication inhibitor ethidium bromide and the mtDNA depletion triggered a universal metabolic remodeling process. [Oncotarget] Full Article

CXCL3 Contributes to CD133⁺ CSCs Maintenance and Forms a Positive Feedback Regulation Loop with CD133 in HCC via Erk1/2 Phosphorylation

In their previous study, researchers found that Ikaros inhibited CD133 expression via the MAPK pathway in hepatocellular carcinoma (HCC). In this study they showed that Ikaros may indirectly down-regulate CXCL3 expression in HCC cells, which leads to better outcomes in patients with CD133⁺ cancer stem cell populations. [Sci Rep] Full Article

Rebamipide Attenuates Helicobacter Pylori CagA-Induced Self-Renewal Capacity via Modulation of β-Catenin Signaling Axis in Gastric Cancer-Initiating Cells

Researchers showed that rebamipide suppresses Helicobacter pylori cagA-induced β-catenin and its target cancer-initiating cells marker gene expression via upregulation of miRNA-320a and -4496. [Biochem Pharmacol] Abstract

Targeting Highly Expressed Extracellular HSP90 in Breast Cancer Stem Cells Inhibits Tumor Growth In Vitro and In Vivo

Scientists showed for the first time that eHSP90 is over-expressed in mammosphere cultures that are derived from the MDA-MB-231, MDA-MB-453 and MCF-7 breast cancer cell lines. These mammospheres are highly enriched in cells of the CD44⁺/CD24^-/low breast cancer stem cells (BCSC) phenotype and additionally show high expression of the BCSC markers CD49f and Sox2. Their results indicate that eHSP90 represents a potential novel BCSC marker. [Cancer Biol Ther] Abstract

Combination Therapy Targeting Both Cancer Stem-Like Cells and Bulk Tumor Cells for Improved Efficacy of Breast Cancer Treatment

The authors generated an in vitro mammosphere of two breast cancer cell lines, and demonstrated the mammosphere to grow and enrich cancer cells with stem-like properties, including self-renewal, multilineage differentiation and enrichment of cells expressing breast cancer stem-like cell biomarkers CD44⁺/CD24^-/low. [Cancer Biol Ther] Abstract

Class I HDAC Inhibitor Mocetinostat Induces Apoptosis by Activation of miR-31 Expression and Suppression of E2F6

In an orthotopic xenograft model, scientists demonstrated that mocetinostat activated miR-31, decreased E2F6, induced apoptosis, and significantly reduced prostate cancer growth. Importantly, they found that mocetinostat also increased miR-31 expression, decreased E2F6, and induced apoptosis in the primary prostate cancer stem cells. [Cell Death Discov] Full Article

The Isomerase PIN1 Controls Numerous Cancer-Driving Pathways and Is a Unique Drug Target

PIN1 is over activated in cancers and it promotes cancer and cancer stem cells by disrupting the balance of oncogenes and tumor suppressors. The reviewers discuss the roles of PIN1 in cancer and the potential of PIN1 inhibitors to restore this balance. [Nat Rev Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Boston Biomedical Featured Seven Clinical Posters on Cancer Stem Cell Pathway Inhibitors Napabucasin and Amcasertib in Multiple Cancer Types

Boston Biomedical featured clinical data on investigational compounds napabucasin (BBI-608) and amcasertib (BBI-503) in multiple tumor types. Data highlighted the potential of napabucasin – an orally administered investigational cancer stemness inhibitor designed to inhibit cancer stem cell pathways by targeting STAT3 – to promote anti-cancer activity when used in combination with other chemotherapeutics. [Press release from Boston Biomedical discussing research presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release

Moffitt Researchers Report Improved Progression-Free Survival and Responses Rates for Lutathera over Octreotide in Patients with Progressive Metastatic Midgut Neuroendocrine Tumors

Moffitt Cancer Center presented results of the Phase III NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors. [Press release from Moffitt Cancer Center discussing research presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release

Froedtert & the Medical College of Wisconsin Taps Watson for Clinical Trial Matching

IBM announced Froedtert & the Medical College of Wisconsin Cancer Network will adopt Watson cognitive computing to help match cancer patients with clinical trials. The Froedtert & MCW Cancer Network is the first in Wisconsin and among the first cancer programs in the nation to use Watson for Clinical Trial Matching. The matching program is slated to begin this fall. [IBM] Press Release

BluePen Biomarkers Announces Collaboration with the University of Pennsylvania to Develop Strategic ‘Multi-Omics’ Platform for Integrated Biomarker Discovery

The University of Pennsylvania has co-founded and structured BluePen Biomarkers in collaboration with Blueprint Bio, Inc. and Emerald Logic, Inc. to conduct biomarker research and identification. BluePen is creating a comprehensive biomarker measurement and discovery pipeline for the acceleration of personalized medicine. [Blueprint Bio, Inc. (PR Newswire Association LLC)] Press Release

NEW 7^th International Conference on Stem Cells and Cancer (ICSCC-2016): Proliferation, Differentiation and Apoptosis
October 21-23, 2016
Goa, India

Visit our events page to see a complete list of events in the cancer stem cell community.

NEW Postdoctoral Fellow – Cancer Stem Cell Biology (Cleveland Clinic Lerner Research Institute)

NEW Postdoctoral Fellow – Biology of Tumor Initiating Cells (German Cancer Research Center)

NEW Assistant Professor – Molecular Pharmacology, Systems Biology, Cancer Therapeutics (German Cancer Research Center)

Senior Research Scientist – Drug Discovery in Cancer (Vertex Pharmaceuticals)

Team Leader – Immune-Oncology (Fondation Toulouse Cancer Sante)

Postdoctoral Researcher – Cancer Stem Cells (Institut d’Investigació Biomèdica de Girona)

Postdoctoral Training Fellow – Role of RNA Polymerase III in Cancer (Institute of Cancer Research)

Associate Director – Scientific Operations (Dana-Farber Cancer Institute)

Senior Scientist and Laboratory Manager – Novel Biomarkers of Disease (Manchester Cancer Research Centre)

Associate Director – Translational Science Oncology (AstraZeneca)

Postdoctoral Fellow – Adaptive T-Cell Therapy for Cancer (Memorial Sloan Kettering Cancer Center)

Postdoctoral Fellow – Myeloid Cells in Cancer Patients (The Wistar Institute)

Faculty Position – Multidisciplinary Research Programs (St. Jude Children’s Research Hospital)

Postdoctoral Fellow – Genome and Epigenome of Pediatric Cancer (St. Jude Children’s Research Hospital)

Group Leader – Normal Epithelium and Cancer Stem Cells (Institut Curie)

Postdoctoral Fellow – Prostate Epithelial Homeostasis and Carcinogenesis (Baylor College of Medicine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.